Canagliflozin outperforms sitagliptin in diabetes study

06/28/2013 | Family Practice News

Data on 1,020 metformin-treated type 2 diabetes patients revealed those who took canagliflozin attained lower fasting plasma glucose and showed greater improvements in glycemic control, body weight and blood pressure at 52 weeks than those who either took sitagliptin or placebo followed by sitagliptin. However, canagliflozin was linked to higher rates of genital mycotic infections and adverse events related to osmotic diuresis compared with the other treatments, researchers reported at the ADA 73rd Scientific Sessions.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC